Regular intake of polyphenol-rich food has been associated with a wide variety of beneficial health effects, including the prevention of cardiovascular diseases. However, the parent flavonoids have mostly low bioavailability and, hence, their metabolites have been hypothesized to be bioactive. One of these metabolites, 3-hydroxyphenylacetic acid (3-HPAA), formed by the gut microbiota, was previously reported to exert vasorelaxant effects ex vivo. The aim of this study was to shed more light on this effect in vivo, and to elucidate the mechanism of action. 3-HPAA gave rise to a dose-dependent decrease in arterial blood pressure when administered i.v. both as a bolus and infusion to spontaneously hypertensive rats. In contrast, no significant changes in heart rate were observed. In ex vivo experiments, where porcine hearts from a slaughterhouse were used to decrease the need for laboratory animals, 3-HPAA relaxed precontracted porcine coronary artery segments via a mechanism partially dependent on endothelium integrity. This relaxation was significantly impaired after endothelial nitric oxide synthase inhibition. In contrast, the blockade of SKCa or IKCa channels, or muscarinic receptors, did not affect 3-HPAA relaxation. Similarly, no effects of 3-HPAA on cyclooxygenase nor L-type calcium channels were observed. Thus, 3-HPAA decreases blood pressure in vivo via vessel relaxation, and this mechanism might be based on the release of nitric oxide by the endothelial layer.

Department of Biological and Medical Sciences Faculty of Pharmacy Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic

Department of Pharmacology and Toxicology Faculty of Pharmacy Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic

Zobrazit více v PubMed

World Health Organization. [(accessed on 10 November 2021)]. Available online: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1.

Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M., Benetos A., Biffi A., Boavida J.-M., Capodanno D., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC) Eur. Heart J. 2021;42:3227–3337. doi: 10.1093/eurheartj/ehab484. PubMed DOI

Vasan R.S., Beiser A., Seshadri S., Larson M.G., Kannel W.B., D’Agostino R.B., Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287:1003–1010. doi: 10.1001/jama.287.8.1003. PubMed DOI

Whelton S.P., McEvoy J.W., Shaw L., Psaty B.M., Lima J.A.C., Budoff M., Nasir K., Szklo M., Blumenthal R.S., Blaha M.J. Association of Normal Systolic Blood Pressure Level with Cardiovascular Disease in the Absence of Risk Factors. JAMA Cardiol. 2020;5:1011–1018. doi: 10.1001/jamacardio.2020.1731. PubMed DOI PMC

Jepps T.A. Unravelling the complexities of vascular smooth muscle ion channels: Fine tuning of activity by ancillary subunits. Pharmacol. Ther. 2017;178:57–66. doi: 10.1016/j.pharmthera.2017.03.010. PubMed DOI

Del Bo C., Bernardi S., Marino M., Porrini M., Tucci M., Guglielmetti S., Cherubini A., Carrieri B., Kirkup B., Kroon P., et al. Systematic Review on Polyphenol Intake and Health Outcomes: Is there Sufficient Evidence to Define a Health-Promoting Polyphenol-Rich Dietary Pattern? Nutrients. 2019;11:1355. doi: 10.3390/nu11061355. PubMed DOI PMC

Panche A.N., Diwan A.D., Chandra S.R. Flavonoids: An overview. J. Nutr. Sci. 2016;5:e47. doi: 10.1017/jns.2016.41. PubMed DOI PMC

Mladenka P., Zatloukalová L., Filipský T., Hrdina R. Cardiovascular effects of flavonoids are not caused only by direct antioxidant activity. Free Radic. Biol. Med. 2010;49:963–975. doi: 10.1016/j.freeradbiomed.2010.06.010. PubMed DOI

Cassidy A., Minihane A.-M. The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids. Am. J. Clin. Nutr. 2016;105:10–22. doi: 10.3945/ajcn.116.136051. PubMed DOI PMC

Williamson G., Kay C.D., Crozier A. The Bioavailability, Transport, and Bioactivity of Dietary Flavonoids: A Review from a Historical Perspective. Compr. Rev. Food Sci. Food Saf. 2018;17:1054–1112. doi: 10.1111/1541-4337.12351. PubMed DOI

Thilakarathna S.H., Rupasinghe H.P.V. Flavonoid bioavailability and attempts for bioavailability enhancement. Nutrients. 2013;5:3367–3387. doi: 10.3390/nu5093367. PubMed DOI PMC

Griffiths L.A., Smith G.E. Metabolism of myricetin and related compounds in the rat. Metabolite formation in vivo and by the intestinal microflora in vitro. Biochem. J. 1972;130:141–151. doi: 10.1042/bj1300141. PubMed DOI PMC

Booth A.N., Deeds F., Jones F.T., Murray C.W. The metabolic fate of rutin and quercetin in the animal body. J. Biol. Chem. 1956;223:251–257. doi: 10.1016/S0021-9258(18)65133-6. PubMed DOI

Najmanová I., Pourová J., Vopršalová M., Pilařová V., Semecký V., Nováková L., Mladěnka P. Flavonoid metabolite 3-(3-hydroxyphenyl)propionic acid formed by human microflora decreases arterial blood pressure in rats. Mol. Nutr. Food Res. 2016;60:981–991. doi: 10.1002/mnfr.201500761. PubMed DOI

Pourova J., Najmanova I., Voprsalova M., Migkos T., Pilarova V., Applova L., Novakova L., Mladenka P. Two flavonoid metabolites, 3,4-dihydroxyphenylacetic acid and 4-methylcatechol, relax arteries ex vivo and decrease blood pressure in vivo. Vascul. Pharmacol. 2018;111:36–43. doi: 10.1016/j.vph.2018.08.008. PubMed DOI

Appeldoorn M.M., Vincken J.-P., Aura A.-M., Hollman P.C.H., Gruppen H. Procyanidin Dimers Are Metabolized by Human Microbiota with 2-(3,4-Dihydroxyphenyl)acetic Acid and 5-(3,4-Dihydroxyphenyl)-γ-valerolactone as the Major Metabolites. J. Agric. Food Chem. 2009;57:1084–1092. doi: 10.1021/jf803059z. PubMed DOI

Feliciano R.P., Boeres A., Massacessi L., Istas G., Ventura M.R., Nunes Dos Santos C., Heiss C., Rodriguez-Mateos A. Identification and quantification of novel cranberry-derived plasma and urinary (poly)phenols. Arch. Biochem. Biophys. 2016;599:31–41. doi: 10.1016/j.abb.2016.01.014. PubMed DOI

Guadamuro L., Jiménez-Girón A.M., Delgado S., Flórez A.B., Suárez A., Martín-Álvarez P.J., Bartolomé B., Moreno-Arribas M.V., Mayo B. Profiling of Phenolic Metabolites in Feces from Menopausal Women after Long-Term Isoflavone Supplementation. J. Agric. Food Chem. 2016;64:210–216. doi: 10.1021/acs.jafc.5b05102. PubMed DOI

Olthof M.R., Hollman P.C., Buijsman M.N., van Amelsvoort J.M., Katan M.B. Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans. J. Nutr. 2003;133:1806–1814. doi: 10.1093/jn/133.6.1806. PubMed DOI

Serra A., Macià A., Romero M.-P., Anglés N., Morelló J.-R., Motilva M.-J. Metabolic pathways of the colonic metabolism of procyanidins (monomers and dimers) and alkaloids. Food Chem. 2011;126:1127–1137. doi: 10.1016/j.foodchem.2010.11.145. DOI

Rechner A.R., Smith M.A., Kuhnle G., Gibson G.R., Debnam E.S., Srai S.K., Moore K.P., Rice-Evans C.A. Colonic metabolism of dietary polyphenols: Influence of structure on microbial fermentation products. Free Radic. Biol. Med. 2004;36:212–225. doi: 10.1016/j.freeradbiomed.2003.09.022. PubMed DOI

Serra A., Macià A., Romero M.-P., Reguant J., Ortega N., Motilva M.-J. Metabolic pathways of the colonic metabolism of flavonoids (flavonols, flavones and flavanones) and phenolic acids. Food Chem. 2012;130:383–393. doi: 10.1016/j.foodchem.2011.07.055. DOI

Liu C., Vervoort J., Beekmann K., Baccaro M., Kamelia L., Wesseling S., Rietjens I.M.C.M. Interindividual Differences in Human Intestinal Microbial Conversion of (−)-Epicatechin to Bioactive Phenolic Compounds. J. Agric. Food Chem. 2020;68:14168–14181. doi: 10.1021/acs.jafc.0c05890. PubMed DOI PMC

Parker J.D., D’ Iorio M., Floras J.S., Toal C.B. Comparison of short-acting versus extended-release nifedipine: Effects on hemodynamics and sympathetic activity in patients with stable coronary artery disease. Sci. Rep. 2020;10:565. doi: 10.1038/s41598-019-56890-1. PubMed DOI PMC

Feng X., Li Y., Brobbey Oppong M., Qiu F. Insights into the intestinal bacterial metabolism of flavonoids and the bioactivities of their microbe-derived ring cleavage metabolites. Drug Metab. Rev. 2018;50:343–356. doi: 10.1080/03602532.2018.1485691. PubMed DOI

Mullen W., Rouanet J.M., Auger C., Teissèdre P.L., Caldwell S.T., Hartley R.C., Lean M.E., Edwards C.A., Crozier A. Bioavailability of [2-(14)C]quercetin-4’-glucoside in rats. J. Agric. Food Chem. 2008;56:12127–12137. doi: 10.1021/jf802754s. PubMed DOI

Bustamante L., Pastene E., Duran-Sandoval D., Vergara C., Von Baer D., Mardones C. Pharmacokinetics of low molecular weight phenolic compounds in gerbil plasma after the consumption of calafate berry (Berberis microphylla) extract. Food Chem. 2018;268:347–354. doi: 10.1016/j.foodchem.2018.06.048. PubMed DOI

Zabela V., Sampath C., Oufir M., Butterweck V., Hamburger M. Single dose pharmacokinetics of intravenous 3,4-dihydroxyphenylacetic acid and 3-hydroxyphenylacetic acid in rats. Fitoterapia. 2020;142:104526. doi: 10.1016/j.fitote.2020.104526. PubMed DOI

Koli R., Erlund I., Jula A., Marniemi J., Mattila P., Alfthan G. Bioavailability of various polyphenols from a diet containing moderate amounts of berries. J. Agric. Food Chem. 2010;58:3927–3932. doi: 10.1021/jf9024823. PubMed DOI

Rodriguez-Mateos A., Feliciano R.P., Cifuentes-Gomez T., Spencer J.P.E. Bioavailability of wild blueberry (poly)phenols at different levels of intake. J. Berry Res. 2016;6:137–148. doi: 10.3233/JBR-160123. DOI

Karlsson P.C., Huss U., Jenner A., Halliwell B., Bohlin L., Rafter J.J. Human fecal water inhibits COX-2 in colonic HT-29 cells: Role of phenolic compounds. J. Nutr. 2005;135:2343–2349. doi: 10.1093/jn/135.10.2343. PubMed DOI

Lelovas P.P., Kostomitsopoulos N.G., Xanthos T.T. A comparative anatomic and physiologic overview of the porcine heart. J. Am. Assoc. Lab. Anim. Sci. 2014;53:432–438. PubMed PMC

Adachi T., Weisbrod R.M., Pimentel D.R., Ying J., Sharov V.S., Schöneich C., Cohen R.A. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat. Med. 2004;10:1200–1207. doi: 10.1038/nm1119. PubMed DOI

Chou T.C., Yen M.H., Li C.Y., Ding Y.A. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension. 1998;31:643–648. doi: 10.1161/01.HYP.31.2.643. PubMed DOI

Malinski T., Kapturczak M., Dayharsh J., Bohr D. Nitric oxide synthase activity in genetic hypertension. Biochem. Biophys. Res. Commun. 1993;194:654–658. doi: 10.1006/bbrc.1993.1871. PubMed DOI

Panza J.A., Casino P.R., Kilcoyne C.M., Quyyumi A.A. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468–1474. doi: 10.1161/01.CIR.87.5.1468. PubMed DOI

Versari D., Daghini E., Virdis A., Ghiadoni L., Taddei S. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br. J. Pharmacol. 2009;157:527–536. doi: 10.1111/j.1476-5381.2009.00240.x. PubMed DOI PMC

Chaudhary P., Pandey A., Azad C.S., Tia N., Singh M., Gambhir I.S. Association of oxidative stress and endothelial dysfunction in hypertension. Anal. Biochem. 2020;590:113535. doi: 10.1016/j.ab.2019.113535. PubMed DOI

Uzun D.K.a.H. Endothelial Dysfunction and Hypertension. In: Islam M.S., editor. Hypertension: From Basic Research to Clinical Practice. Springer International Publishing; Stockholm, Sweden: 2017. pp. 511–515.

Félétou M. Calcium-activated potassium channels and endothelial dysfunction: Therapeutic options? Br. J. Pharmacol. 2009;156:545–562. doi: 10.1111/j.1476-5381.2009.00052.x. PubMed DOI PMC

Dhein S., van Koppen C.J., Brodde O.E. Muscarinic receptors in the mammalian heart. Pharmacol. Res. 2001;44:161–182. doi: 10.1006/phrs.2001.0835. PubMed DOI

Najmanová I., Pourová J., Mladěnka P. A Mixture of Phenolic Metabolites of Quercetin Can Decrease Elevated Blood Pressure of Spontaneously Hypertensive Rats Even in Low Doses. Nutrients. 2020;12:213. doi: 10.3390/nu12010213. PubMed DOI PMC

Satoh H., Nishida S. Cardio-Electopharmacology and Vasodilating Mechanisms of Quercetin. Med. Chem. 2014;4:523–530. doi: 10.4172/2161-0444.1000189. DOI

Rivera L., Morón R., Sánchez M., Zarzuelo A., Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity. 2008;16:2081–2087. doi: 10.1038/oby.2008.315. PubMed DOI

DuPont M.S., Bennett R.N., Mellon F.A., Williamson G. Polyphenols from Alcoholic Apple Cider Are Absorbed, Metabolized and Excreted by Humans. J. Nutr. 2002;132:172–175. doi: 10.1093/jn/132.2.172. PubMed DOI

Gugler R., Leschik M., Dengler H.J. Disposition of quercetin in man after single oral and intravenous doses. Eur. J. Clin. Pharmacol. 1975;9:229–234. doi: 10.1007/BF00614022. PubMed DOI